Supplemental Materials from A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921)
Year: 2023
Type: supplementary-materials
Abstract: Figure S1. Percentage of huCD45+ cells in blood (cardiac bleed) of engrafted mice at treatment initiation, then on Days 7, 21 and 42 for control (light grey), mice treated with Schedule A (7 days, BID, dark grey) or Schedule B (5 days BID X 3, black). The hatched bar corresponds to day 0. Medians and ranges are depicted. Figure S2. Percentage of huCD45+ cells in spleens of engrafted mice at treatment initiation, then on Days 7, 21 and 42 for control (light grey), mice treated with Schedule A (7 days, BID, dark grey) or Schedule B (5 days BID X 3, black). The hatched bar corresponds to day 0. Medians and ranges are depicted. Figure S3. Percentage of huCD45+ cells in bone marrows of engrafted mice at treatment initiation, then on Days 7, 21 and 42 for control (light grey), mice treated with Schedule A (7 days, BID, dark grey) or Schedule B (5 days BID X 3, black). The hatched bar corresponds to day 0. Medians and ranges are depicted. Table S1. Alisertib Pharmacokinetic Parameters Table S2. Summary table of in vivo drug responses
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361887296